Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alphamab OncologyHKSE:09966 +2.58%55 Days Payable is 348.25 as of Dec. 2025, which is 72% above its 10-year median of 202.87. GuruFocus rates HKSE:09966 with a GF Score™ of 55/100 and a GF Value™ of HK$7.81 (Fairly Valued). The stock has 4 warning signs investors should review. Among 703 Biotechnology companies, Alphamab Oncology ranks better than 71.55% on this metric.
The historical rank and industry rank for Alphamab Oncology's Days Payable or its related term are showing as below:
HKSE:09966'
s Days Payable Range Over the Past 10 Years
Min: 105.89 Med: 202.87 Max: 777.3
Current: 310.13
During the past 9 years, Alphamab Oncology's highest Days Payable was 777.30. The lowest was 105.89. And the median was 202.87.
HKSE:09966's Days Payable is ranked better than 71.55% of 703
companies
in the Biotechnology industry
Industry Median: 110.14
vs HKSE:09966: 310.13
Alphamab Oncology's Days Payable
increased
from Dec. 2024 (192.38) to Dec. 2025 (348.25).
It may suggest that Alphamab Oncologydelayed paying its suppliers.
The historical data trend for Alphamab Oncology's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:09966 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Alphamab Oncology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alphamab Oncology Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alphamab Oncology's Days Payable distribution charts can be found below:
* The bar in red indicates where Alphamab Oncology's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Alphamab Oncology's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alphamab Oncology (HKSE:09966) has a Days Payable of 348.25 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Alphamab Oncology and its competitors. This is 72% above median its historical median of 202.87. Over the past decade, Alphamab Oncology's Days Payable has ranged from 105.89 to 777.30. According to the industry distribution chart, Alphamab Oncology ranks #200 out of 703 companies in the Biotechnology industry, placing it in the top 28.4%.
Is Alphamab Oncology's Days Payable too high?
Alphamab Oncology's current Days Payable of 348.25 is 72% above median its 10-year median of 202.87. Over the past 10 years, this metric has ranged from a low of 105.89 to a high of 777.30. The Biotechnology industry median Days Payable is 110.14. Alphamab Oncology's value of 348.25 is 216.2% above this industry median. Based on the distribution chart, Alphamab Oncology ranks #200 out of 703 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Alphamab Oncology has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Alphamab Oncology's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alphamab Oncology ranks #200 out of 703 companies for Days Payable. This puts Alphamab Oncology in the upper half of its industry. The industry median Days Payable is 110.14. Alphamab Oncology's value of 348.25 is 216.2% above this benchmark. Historically, Alphamab Oncology's own Days Payable has ranged from 105.89 to 777.30 over the past decade. While the company's 10-year median is 202.87 vs. the industry median of 110.14, Alphamab Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.14, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alphamab Oncology's current Days Payable of 348.25 is 216.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Alphamab Oncology and its competitors. For the Biotechnology industry, the median Days Payable is 110.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alphamab Oncology's current Days Payable is 348.25, which is 72% above median its own 10-year median of 202.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alphamab Oncology stock overvalued right now?
Based on GuruFocus' analysis, Alphamab Oncology (HKSE:09966) is currently considered Fairly Valued. The stock's GF Value™ is HK$7.81, compared to a current price of HK$8.35 — trading 6.9% above its estimated fair value. The current Days Payable is 348.25, which is 72% above median its 10-year median of 202.87 and 216.2% above the Biotechnology industry median of 110.14. Alphamab Oncology's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Alphamab Oncology (HKSE:09966), the current Days Payable is 348.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alphamab Oncology (HKSE:09966) Overvalued in 2026?
Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued.
The current stock price of HK$8.35 is trading 6.9% above its estimated GF Value™ of HK$7.81.
GuruFocus considers Alphamab Oncology to be Fairly Valued.
Key valuation signals for HKSE:09966:
Days Payable: 348.25 (72% above median its 10-year median of 202.87)
GF Value™: HK$7.81 vs. price of HK$8.35 (6.9% above fair value)
Industry Position: 216.2% above the Biotechnology median (#200 of 703)
No single metric tells the full story. See the HKSE:09966 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
55GF Score
Get the complete analysis for HKSE:09966
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09966 has been successfully added to your 
